Belantamab

• Description:

  Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239) . After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma[1][2].

• Product Name Alternative:

  GSK2857914

• UNSPSC:

  12352203

• Target:

  ADC Antibody; TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/belantamab.html

• Purity:

  99.90

• Solubility:

  H2O

• Smiles:

  [Belantamab]

• Molecular Weight:

  (146.06 kDa)

• References & Citations:

  [1]Ivo Demel, et al. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021 May;193 (4) :705-722.|[2]Montes de Oca R, et al. Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo. Mol Cancer Ther. 2021 Oct;20 (10) :1941-1955.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 3

• CAS Number:

  2061894-48-0